Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine versus midazolam plus morphine for prevention of depression, anxiety, and PTSD after ICU discharge
IRCT20170413033408N5Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in major depressive disorder (MDD), anxiety disorder and post-traumatic stress disorder (PTSD) comparing Ketamine with Midazolam plus morphine control (2 arms). Primary endpoints: Rate of depressive disorders, Rate of anxiety disorders and 1 more. Started Feb 2021; status: completed.
02
Drugs
ketaminemidazolammorphine
03
Conditions
major depressive disorder (MDD)anxiety disorderpost-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on IRCT20170413033408N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170413033408N5.